Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gaspar

Showing results (211-220 of 221) with videos related to

Pageof 23
Sort By:
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Schizophrenia (Heidelberg, Germany)|June 6, 2025
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measuresDaniel H Mathalon, Spero Nicholas, Brian J Roach, et al.
Nature Genetics|July 17, 2019
Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosaHunna J Watson, Zeynep Yilmaz, Laura M Thornton, et al.
Schizophrenia Bulletin|March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for PsychosisCassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Nature Genetics|April 28, 2018
Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depressionNaomi R Wray, Stephan Ripke, Manuel Mattheisen, et al.
Nature Genetics|May 3, 2019
Genome-wide association study identifies 30 loci associated with bipolar disorderEli A Stahl, Gerome Breen, Andreas J Forstner, et al.
Pageof 23

Showing results (211-220 of 221) with videos related to

Sort By:
Pageof 23
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Schizophrenia (Heidelberg, Germany)|June 6, 2025
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measuresDaniel H Mathalon, Spero Nicholas, Brian J Roach, et al.
Nature Genetics|July 17, 2019
Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosaHunna J Watson, Zeynep Yilmaz, Laura M Thornton, et al.
Schizophrenia Bulletin|March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for PsychosisCassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Nature Genetics|April 28, 2018
Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depressionNaomi R Wray, Stephan Ripke, Manuel Mattheisen, et al.
Nature Genetics|May 3, 2019
Genome-wide association study identifies 30 loci associated with bipolar disorderEli A Stahl, Gerome Breen, Andreas J Forstner, et al.
Pageof 23